InvestSMART

Argenica Therapeutics Limited (ASX:AGN)

ALERT: Price-sensitive ASX Announcement for AGN
Current share price for AGN : $0.170 0.02 (13.33%)+
Announcement
Release
24 Jul 2026 9:18AM
Price at Release
$0.150
Full Release
download
Summary
Argenica Therapeutics Limited, an Australian biotechnology company, is focused on developing its lead neuroprotective drug candidate ARG-007 (xaranetide) to reduce brain tissue death following strokes. The company has completed a Phase 2 clinical trial and is preparing for a late-stage trial, supported by $1.5 million in government funding. Argenica is advancing drug manufacturing processes and plans to submit a trial protocol to the FDA. Preclinical studies have shown promising results for ARG-007 in treating traumatic brain injuries. By the end of June 2026, the company maintained cash reserves of $6.35 million.
Key Points
  • Argenica Therapeutics Limited is developing the drug ARG-007, also known as xaranetide, to reduce brain tissue death after stroke.
  • The company completed a Phase 2 clinical trial of ARG-007 in acute ischemic stroke (AIS) patients and is preparing for a late-stage clinical trial.
  • Argenica received $1.5 million in non-dilutive funding from the Australian Government’s Medical Research Future Fund to support the clinical trial.
  • The company has secured over $4 million in grant and philanthropic funding for its projects from various organizations.
  • During the quarter, Argenica advanced drug substance manufacturing with Corden Pharma to support clinical trials and future supply.
  • Argenica aims to submit a trial protocol to the FDA and seek approval for an Investigational New Drug (IND) application for ARG-007.
  • The World Health Organization confirmed the International Nonproprietary Name xaranetide for ARG-007.
  • Preclinical studies showed xaranetide's efficacy in reducing neuroinflammation and oxidative stress in traumatic brain injury models.
  • The company reported cash reserves of $6.35 million at the end of June 2026, with net operating cash outflows of $1.605 million for the quarter.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.